iShares iBonds Dec 2032 Term Corporate ETF (NYSEARCA:IBDX – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $24.89 and last traded at $24.90, with a volume of 73891 shares. The stock had previously closed at $24.97.
iShares iBonds Dec 2032 Term Corporate ETF Stock Down 0.3%
The business’s 50-day moving average price is $25.11 and its 200-day moving average price is $25.35.
Hedge Funds Weigh In On iShares iBonds Dec 2032 Term Corporate ETF
Hedge funds have recently modified their holdings of the stock. Ballast Advisors LLC purchased a new stake in shares of iShares iBonds Dec 2032 Term Corporate ETF during the first quarter worth $30,000. Bogart Wealth LLC acquired a new position in iShares iBonds Dec 2032 Term Corporate ETF in the 4th quarter worth about $56,000. Ascentis Independent Advisors purchased a new stake in shares of iShares iBonds Dec 2032 Term Corporate ETF during the 1st quarter worth about $88,000. Jupiter Wealth Management LLC purchased a new stake in shares of iShares iBonds Dec 2032 Term Corporate ETF during the 2nd quarter worth about $130,000. Finally, Crews Bank & Trust lifted its holdings in shares of iShares iBonds Dec 2032 Term Corporate ETF by 91.8% during the 4th quarter. Crews Bank & Trust now owns 5,755 shares of the company’s stock valued at $147,000 after buying an additional 2,755 shares during the last quarter.
About iShares iBonds Dec 2032 Term Corporate ETF
The iShares iBonds Dec 2032 Term Corporate ETF (IBDX) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund tracks a Bloomberg index of USD-denominated, investment grade corporate bonds maturing between January 1, 2032 and December 15, 2032. IBDX was launched on Jun 28, 2022 and is managed by BlackRock.
Featured Articles
- Five stocks we like better than iShares iBonds Dec 2032 Term Corporate ETF
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
- The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
- Why Micron Is Doubling Down While the HBM Shortage Persists
Receive News & Ratings for iShares iBonds Dec 2032 Term Corporate ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares iBonds Dec 2032 Term Corporate ETF and related companies with MarketBeat.com's FREE daily email newsletter.
